30 closest matches · ranked by relevance
Systemic Sclerosis-Associated PAH
Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12
Systemic Sclerosis · Shortness of Breath · Pulmonary Hypertension
Primary: Change in Exercise Pulmonary Hemodynamics From Baseline to Week 24 — 37.4 mmHg — p=.0008
Pulmonary Arterial Hypertension · Systemic Sclerosis · Scleroderma Spectrum of Diseases
Primary: Right Ventricular (RV) Mass — 32.5; 28.0 grams
Systemic Sclerosis · Pulmonary Hypertension
Primary: Mean Pulmonary Arterial Pressure Change From Baseline — -1.0; -0.73 mmHg
Systemic Sclerosis · Scleroderma
Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…
Scleroderma, Systemic
Primary: Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52 — -2.088; -0.769 score on a scale — p=0.0815
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Scleroderma, Systemic · Scleroderma, Diffuse · Scleroderma, Limited
Primary: Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) Before Cold Stimulus — 260.0; 246.3 perfusion units
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Scleroderma · Digital Ulcers
Primary: Change From Baseline to End of Double-blind Treatment (Week 16) in Digital Ulcer Net Burden — -1.22; -0.98 ulcers — p=0.70
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks — 1.28 mL/min/kg
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214
Scleroderma, Systemic · Interstitial Lung Disease
Primary: Percent Predicted Forced Vital Capacity (FVC-%) — 2.24; 2.09 percent predicted — p=0.9326
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
Pulmonary Arterial Hypertension
Primary: Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks — -27.6; -168.4; -258.9; 802.0 dynes*sec/cm^5 — p=0.0030
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 — -2.45; -4.76 score on a scale — p=0.0291
Scleroderma, Systemic
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -93.3; -52.4 millilitre (mL)/year (yr) — p=0.0350
Systemic Sclerosis · Calcinosis
Primary: Number of Participants With Treatment-related Adverse Events Following Treatment With Oral Treprostinil — 11 Participants
n Ulcer · Scleroderma, Systemic
Primary: New Digital Ulcers (DU) 4 Weeks Prior to Week 24 — 0.06 new digital ulcers
Pulmonary Hypertension
Primary: 6 Minute Walk Distance — 419.1; 418.1; 436.5; 377.1 meters — p=0.68
Pulmonary Arterial Hypertension · Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — 230 meters
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Hypertension · Pulmonary Arterial Hypertension · Familial Primary Pulmonary Hypertension
Primary: Transthoracic Echocardiogram (ECHO)-Based Change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) Measurement — 2.244; 2.244; 2.300; 2.212 mm
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Primary: Change in Frequency of Symptomatic RP Attacks — -11.47; -12.73 Number of RP attacks per week — p=0.4210
Ischemia
Primary: Digital Micro-vascular Flow — .11; .18; -.01; -.06 perfusion unit
Digital Ulcers
Primary: Time to Complete Healing of Each Baseline DU